Clinical research studies for new indications were reported by the FDA concerning a company identified as Cpt.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Clinical research studies for new indications were reported by the FDA concerning a company identified as Cpt.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- A program linked students to hi-tech employment.Sub-event
Clinical research studies for new indications reported by the FDA.1 source
Keep exploring
The entities involved
Related events
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Nektar Therapeutics is seeking FDA review for its late-stage drug trials.
- FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.